Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Wheeler

Showing results (221-230 of 454) with videos related to

Pageof 46
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 24, 2020
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS ProgramBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
Kidney International|January 23, 2019
Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceBrad H Rovin, Dawn J Caster, Daniel C Cattran, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 23, 2017
Nephrologists' Perspectives on Defining and Applying Patient-Centered Outcomes in HemodialysisAllison Tong, Wolfgang C Winkelmayer, David C Wheeler, et al.
Kidney International|December 17, 2009
Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphismsBen Caplin, Dorothea Nitsch, Herpreet Gill, et al.
Annals of Medicine|June 23, 2026
The impact of multiple long-term conditions on mortality, progression to kidney failure and health-related quality of life among people with chronic kidney disease: a multicentre cohort study (NURTuRE-CKD)Irene Boateng, Thomas Phillips, Scott Harris, et al.
Journal of the American Society of Nephrology : JASN|October 24, 2023
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease ProgressionHiddo J L Heerspink, Niels Jongs, Patrick Schloemer, et al.
Kidney360|July 25, 2024
Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective CohortSteven Fishbane, Juan-Jesus Carrero, Supriya Kumar, et al.
Kidney International|January 18, 2013
Novel techniques and innovation in blood purification: a clinical update from Kidney Disease: Improving Global OutcomesChristopher T Chan, Adrian Covic, Jonathan C Craig, et al.
Kidney International|April 29, 2023
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trialsHiddo J L Heerspink, Niels Jongs, Brendon L Neuen, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 30, 2024
Baseline, Early Changes, and Residual Albuminuria: Post Hoc Analysis of a Randomized Clinical Trial of Dapagliflozin in Chronic Kidney DiseaseDominique van Mil, Priya Vart, Glenn M Chertow, et al.
Pageof 46

Showing results (221-230 of 454) with videos related to

Sort By:
Pageof 46
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 24, 2020
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS ProgramBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
Kidney International|January 23, 2019
Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceBrad H Rovin, Dawn J Caster, Daniel C Cattran, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 23, 2017
Nephrologists' Perspectives on Defining and Applying Patient-Centered Outcomes in HemodialysisAllison Tong, Wolfgang C Winkelmayer, David C Wheeler, et al.
Kidney International|December 17, 2009
Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphismsBen Caplin, Dorothea Nitsch, Herpreet Gill, et al.
Annals of Medicine|June 23, 2026
The impact of multiple long-term conditions on mortality, progression to kidney failure and health-related quality of life among people with chronic kidney disease: a multicentre cohort study (NURTuRE-CKD)Irene Boateng, Thomas Phillips, Scott Harris, et al.
Journal of the American Society of Nephrology : JASN|October 24, 2023
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease ProgressionHiddo J L Heerspink, Niels Jongs, Patrick Schloemer, et al.
Kidney360|July 25, 2024
Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective CohortSteven Fishbane, Juan-Jesus Carrero, Supriya Kumar, et al.
Kidney International|January 18, 2013
Novel techniques and innovation in blood purification: a clinical update from Kidney Disease: Improving Global OutcomesChristopher T Chan, Adrian Covic, Jonathan C Craig, et al.
Kidney International|April 29, 2023
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trialsHiddo J L Heerspink, Niels Jongs, Brendon L Neuen, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 30, 2024
Baseline, Early Changes, and Residual Albuminuria: Post Hoc Analysis of a Randomized Clinical Trial of Dapagliflozin in Chronic Kidney DiseaseDominique van Mil, Priya Vart, Glenn M Chertow, et al.
Pageof 46